Neurogene Inc. (NASDAQ:NGNE) recently witnessed substantial stock acquisitions by Samsara BioCapital, L.P. and its affiliates. On November 26, Samsara BioCapital acquired a total of 48,770 shares of Neurogene's common stock, with transaction prices ranging from $24.91 to $27.50 per share. The cumulative value of these purchases amounted to approximately $1,259,622.
These acquisitions were executed across multiple transactions, with the shares held indirectly by Samsara BioCapital, L.P. Srinivas Akkaraju, a managing member of Samsara BioCapital GP, LLC, holds voting and investment power over these shares. The purchases reflect Samsara BioCapital's continued interest in Neurogene, a company focused on pharmaceutical preparations.
The transactions highlight Samsara BioCapital's strategic positioning in Neurogene, as it holds a significant stake, further strengthening its influence in the company.
In other recent news, Neurogene has seen significant developments with its Rett syndrome treatment, NGN-401. Despite a severe adverse event (SAE) in a patient treated with a high dose of the drug, the U.S. Food and Drug Administration (FDA) has allowed Neurogene to proceed with trials at a lower dose. H.C. Wainwright reaffirmed its Buy rating for Neurogene, maintaining confidence in the drug's potential at lower doses.
Stifel and BMO Capital Markets have also maintained positive outlooks for Neurogene, despite adjusting their stock price targets in light of recent events. Furthermore, Neurogene reported a net loss of $18.5 million in Q2 2024, with R&D expenses reaching $15.7 million. The company secured approximately $200 million in oversubscribed PIPE financing, which is expected to support the completion of enrollment for the NGN-401 study into the second half of 2027.
Neurogene also terminated its Batten's disease program recently. Looking ahead, Neurogene anticipates providing updates on the pivotal trial design in the first half of 2025 and expects to release more interim Phase 1/2 data in the second half of 2025. These recent developments underscore the ongoing efforts by Neurogene to advance its investigational therapy, NGN-401.
InvestingPro Insights
Neurogene Inc.'s recent stock acquisitions by Samsara BioCapital align with some intriguing financial metrics and trends revealed by InvestingPro data. The company's market capitalization stands at $382.21 million, reflecting its current valuation in the pharmaceutical sector.
One of the most striking InvestingPro Tips is that Neurogene holds more cash than debt on its balance sheet. This strong liquidity position could be a factor attracting institutional investors like Samsara BioCapital, as it provides the company with financial flexibility to pursue its pharmaceutical development initiatives.
Additionally, Neurogene has experienced a significant return over the last week, with a 75.28% price total return. This recent surge in stock price might have influenced Samsara BioCapital's decision to increase its stake, potentially seeing it as an opportune moment to strengthen its position.
However, it's worth noting that Neurogene is currently not profitable, with a negative gross profit margin of -6132.86% in the last twelve months as of Q3 2024. This aligns with another InvestingPro Tip indicating that analysts do not anticipate the company will be profitable this year.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for Neurogene, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.